Is it enough just to demonstrate that the advanced therapy medicinal products do work or we would prefer to keep walking on the Moon?
After several decades of continuous yet bumpy progress the advanced therapy medicinal products reached the stage when the first drugs with well documented efficacy started to be registered. However, in the disturbing chain of events, many of them were discontinued because of the lack of return on in...
Main Author: | Dinko Mitrečić |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | Regenerative Therapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352320423000512 |
Similar Items
-
Is the Conjunctiva a Potential Target for Advanced Therapy Medicinal Products?
by: Yolanda Diebold, et al.
Published: (2021-07-01) -
Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework
by: Marina López-Paniagua, et al.
Published: (2021-03-01) -
Mesenchymal stem cell therapy for neurological disorders: The light or the dark side of the force?
by: Jasmina Isaković, et al.
Published: (2023-02-01) -
Projecting direct medical costs and productivity benefits of improving access to advanced therapy for rheumatoid arthritis: a projection modelling study
by: Chee Yoong Foo, et al.
Published: (2023-12-01) -
Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?
by: Jen-Hao Yeh, et al.
Published: (2022-06-01)